ERBB2 and non-small cell lung carcinoma: In clinical practice, HER2-targeted monoclonal antibodies and tyrosine kinase inhibitors serve as the primary treatment modalities for advanced or metastatic HER2-positive breast and gastric/gastroesophageal adenocarcinomas, as well as HER2-mutant non-small cell lung cancer (NSCLC) (Cervantes et al., 2023).